Estrogen News and Research

Latest Estrogen News and Research

Age-related decline in cardiac conduction system regeneration increases arrhythmia risk after heart attack

Study uncovers the impact of myocardial infarction on the cardiac conduction system, revealing insights into arrhythmogenesis and potential therapeutic targets.

8 Jan 2025

Study finds microRNA target to combat breast cancer treatment resistance

A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.

7 Jan 2025

Specialized bone marrow niches reveal secrets of immune tolerance

Researchers have uncovered a hierarchical structure of immune-privileged stem cells in bone marrow niches, revealing their regenerative potential and therapeutic relevance.

2 Jan 2025

Estrogen's role in female binge drinking revealed by preclinical study

The hormone estrogen regulates binge drinking in females, causing them to "pregame" – consume large quantities of alcohol in the first 30 minutes after it's offered, according to a preclinical study led by scientists at Weill Cornell Medicine.

30 Dec 2024

Hippocampal inflammation affects behavior differently in males and females

Inflammation in the hippocampus – the brain's memory centre – significantly alters motivation and behavior in mice, including food-seeking behaviour, with notable differences between males and females, a recent study reveals.

18 Dec 2024

Genetic shifts in reproductive traits link to aging and health risks

This study explores the genetics of human reproductive traits, revealing links to aging, health outcomes, and longevity while highlighting the role of genetic factors in modern fertility shifts.

17 Dec 2024

Genetic insights into reproductive health and longevity

Led by researchers from the University of Oxford's Leverhulme Centre for Demographic Science and the University of Iceland, the review explores how genetic variations can explain differences in reproductive health and longevity.

14 Dec 2024

Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Multi-omic profiling sheds light on chemo-immunotherapy resistance in lung cancer

The study characterizes the lung cancer tumor microenvironment, linking cellular compositions to immunotherapy resistance and potential therapeutic strategies.

13 Dec 2024

PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer

Alliance Foundation Trials, LLC (AFT) and Pfizer Inc. today announced results from the phase III PATINA trial demonstrating that the addition of palbociclib (IBRANCE) to current standard-of-care first-line maintenance therapy (following induction chemotherapy) resulted in statistically significant and clinically meaningful improvement in progression-free survival (PFS) by investigator assessment in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).

12 Dec 2024

Imlunestrant offers new hope for ER-positive HER2-negative breast cancer

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, HER2-negative advanced breast cancer - as monotherapy in patients with ESR1 mutations and as combination therapy with abemaciclib (Verzenio) in all patients, regardless of ESR1 mutation status - according to results from the phase III EMBER-3 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Early ovarian removal and APOE4 increase Alzheimer's risk in women

New research published by a team of researchers from the University of Toronto in collaboration with colleagues from the University of Alberta has found that women who have had both ovaries surgically removed before the age of 50 and carry a variant of the apolipoprotein gene, the APOE4 allele, are at high risk of late-life Alzheimer disease (AD). Use of hormone therapy mitigates this risk.

5 Dec 2024

New insights into survival of breast cancer cells in the bone marrow

A study from researchers at the University of Michigan and the University of California San Diego has shed light on a previously poorly understood aspect of breast cancer recurrence: how cancer cells survive in bone marrow despite targeted therapies.

4 Dec 2024

Study links menopause hormone therapy to varied heart and blood clot risks

Research on hormone therapy reveals critical insights into cardiovascular disease risks, guiding clinicians in selecting safer treatment options for menopause.

3 Dec 2024

Men face sharper brain aging from obesity and heart risks

Obesity and cardiovascular risk factors accelerate brain volume loss, with males experiencing earlier and more significant impacts, highlighting the importance of early interventions to prevent neurodegeneration.

1 Dec 2024

Hormone therapy in early menopause proves safe but lacks cognitive benefits

Early menopausal hormone therapy neither benefits nor harms long-term cognition, offering reassurance but no protection against cognitive decline in healthy women.

26 Nov 2024

Short-term menopausal hormone therapy shows no long-term cognitive effects

Short-term menopausal hormone therapy (MHT) did not have long-term cognitive effects when given to women in early postmenopause, according to a study published November 21st in the open-access journal PLOS Medicine by Carey Gleason from the University of Wisconsin-Madison, USA, and colleagues.

22 Nov 2024